Evidence mapPaperPMID 23378607Full record

ArticleDiabetes2013

Pioglitazone acutely reduces energy metabolism and insulin secretion in rats.

Julien Lamontagne, Elise Jalbert-Arsenault, Emilie Pepin, Marie-Line Peyot, Neil B Ruderman, Christopher J Nolan, Erik Joly, S R Murthy Madiraju, Vincent Poitout, Marc Prentki

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cardiovascular impact of drugs used in the treatment of diabetes.Therapeutic advances in chronic disease · 2014 · on this map
    Review
  19. Divergent compensatory responses to high-fat diet between C57BL6/J and C57BLKS/J inbred mouse strains.American journal of physiology. Endocrinology and metabolism · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Julien LamontagneMolecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, Quebec, Canada.
Elise Jalbert-Arsenault
Emilie Pepin
Marie-Line Peyot
Neil B Ruderman
Christopher J Nolan
Erik Joly
S R Murthy Madiraju
Vincent Poitout
Marc Prentki
Centre Hospitalier de l’Université de Montréal · CAUniversité de Montréal · CAAustralian National University · AUBoston Medical Center · US

Funding

MALONYL COA, MUSCLE FUEL METABOLISM AND OBESITYR01DK019514 · BOSTON UNIVERSITY MEDICAL CENTER HOSP · 1986 to 2005
$1.6M
NIDDK NIH HHS R01 DK019514NIDDK NIH HHS R01DK019514-31
6 · The paper itself

Abstract

Our objective was to determine if the insulin-sensitizing drug pioglitazone acutely reduces insulin secretion and causes metabolic deceleration in vivo independently of change in insulin sensitivity. We assessed glucose homeostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp studies and energy expenditure by indirect calorimetry and biotelemetry in male Wistar and obese hyperinsulinemic Zucker diabetic fatty (ZDF) rats 45 min after a single oral dose of pioglitazone (30 mg/kg). In vivo insulin secretion during clamped hyperglycemia was reduced in both Wistar and ZDF rats after pioglitazone administration. Insulin clearance was slightly increased in Wistar but not in ZDF rats. Insulin sensitivity in Wistar rats assessed by the hyperinsulinemic-euglycemic clamp was minimally affected by pioglitazone at this early time point. Pioglitazone also reduced energy expenditure in Wistar rats without altering respiratory exchange ratio or core body temperature. Glucose-induced insulin secretion (GIIS) and oxygen consumption were reduced by pioglitazone in isolated islets and INS832/13 cells. In conclusion, pioglitazone acutely induces whole-body metabolic slowing down and reduces GIIS, the latter being largely independent of the insulin-sensitizing action of the drug. The results suggest that pioglitazone has direct metabolic deceleration effects on the β-cell that may contribute to its capacity to lower insulinemia and antidiabetic action.

Indexed as

AnimalsCalorimetry, IndirectEnergy MetabolismGlucoseHypoglycemic AgentsInsulinInsulin SecretionMaleOxygen ConsumptionPioglitazoneRatsRats, WistarThiazolidinedionesGlucoseHypoglycemic AgentsInsulinPioglitazoneThiazolidinediones

Identifiers

PMID23378607
PMCPMC3661607
OpenAlexW2017304883

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.